Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus

Aktürk, Müjde; Arslan, Metin; Altınova, Alev Eroğlu; Özdemir, Ayşegül; Ersoy, Reyhan; Yetkin, İlhan; Ayvali, Elif; Gönen, Sevim; Törüner, Füsun Baloş

doi:10.1016/j.ghir.2007.01.007

Cited by 16 publications

(10 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It was also reported that IGF‐1 could inhibit the activity of metalloproteinase‐2 to promote collagen degradation in part of the kidney, which resulted in glomerular sclerosis and eventually led to the death of end‐stage DN patients. However, Akturk et al . showed that mean serum IGF‐I levels in diabetic patients were lower than the non‐diabetic controls.…”

Section: Discussionmentioning

confidence: 99%

Elevated expression levels of serum insulin‐like growth factor‐1, tumor necrosis factor‐α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy

Chen

et al. 2016

J of Diabetes Invest

View full text Add to dashboard Cite

Aims/IntroductionThe present study aimed to determine the associations between expressions of insulin‐like growth factor‐1 (IGF‐1), tumor necrosis factor‐α (TNF‐α) and vascular endothelial growth factor 165 (VEGF 165) in serum, and occurrence and development of type 2 diabetic nephropathy (DN).Materials and MethodsA total of 108 patients diagnosed as DN were randomly selected, including 50 patients in the microalbuminuria group, 44 patients in the macroalbuminuria group and 14 patients in the renal insufficiency group. Meanwhile, 97 healthy people were collected as a normal control group. Urinary albumin (UALB) and urine creatinine (Cr) of all participants were measured for 24 h, with their ratio (UALB/Cr) being calculated. Enzyme‐linked immunosorbent assay was used to detect the serum concentrations of IGF‐1, TNF‐α and VEGF 165.ResultsThe expressions of serum IGF‐1, TNF‐α and VEGF 165 in the type 2 DN patients were significantly higher than those in the control group (all P < 0.05). The expressions of serum IGF‐1, TNF‐α and VEGF 165 in the type 2 DN patients were positively correlated with UALB/Cr (all P < 0.05). As type 2 DN worsened, the expressions of serum IGF‐1, TNF‐α and VEGF 165 increased, and type 2 DN severity had positive correlations with serum IGF‐1, TNF‐α and VEGF 165 concentrations (all P < 0.05). There was a positive association between IGF‐1 and TNF‐α, IGF‐1 and VEGF 165, and TNF‐α and VEGF 165 (all P < 0.05). Logistic regression analysis showed that IGF‐1 and VEGF 165 were associated with the progression of DN (both P < 0.05).ConclusionsElevated expression levels of serum IGF‐1, TNF‐α and VEGF 165 might exacerbate type 2 DN.

show abstract

Section: Discussionmentioning

confidence: 99%

Elevated expression levels of serum insulin‐like growth factor‐1, tumor necrosis factor‐α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy

Chen

et al. 2016

J of Diabetes Invest

View full text Add to dashboard Cite

show abstract

“…IGF binding protein (IGFBP) 3 is a member of the IGFBP family, which regulates components of the IGF signaling pathway (10). IGFBP-3 has been demonstrated to inhibit cell proliferation, independently of its effects on IGF-stimulated growth, in numerous types of malignancies (11,12). Additionally, it has been reported that the expression levels of IGFBP-3 correlate with the response of the patient to radiotherapy and may serve as a marker for the chemosensitivity of glioblastoma to semustine (13).…”

Section: Introductionmentioning

confidence: 99%

Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma

Yan

Yang

et al. 2017

Oncology Letters

View full text Add to dashboard Cite

Abstract. Insulin-like growth factor binding protein-3 (IGFBP-3) has previously been identified as a putative tumor suppressor gene. The present study investigated the clinical and prognostic significance of IGFBP-3 expression levels in patients with hepatocellular carcinoma (HCC). Immunohistochemistry (IHC) probing for IGFBP-3 was performed on paraffin-embedded tissue samples obtained from 120 patients with HCC, including tissue samples from 120 primary cancer sites and 50 matched adjacent non-malignant sites. Receiver-operator curve (ROC) analysis was used to determine the cut-off scores for the presence of IGFBP-3-positive tumor cells and to estimate the survival time of the patients. The threshold for marking the positive expression of IGFBP-3 was 65%, based on the area under the ROC. Positive expression of IGFBP-3 was observed in 65/120 (54.2%) of the HCC tissues, and in 36/50 (72%) of the adjacent non-malignant liver tissues. Low levels of IGFBP-3 expression were correlated with tumor size (P=0.003), tumor multiplicity (P=0.044), node (P=0.008), metastasis (P=0.001) and clinical stage (P=0.001), as well as reduced survival time (P= 0.015). Using univariate survival analysis, a significant direct correlation between high and low IGFBP-3 expression levels, and patient survival time (mean survival time high IGFBP-3, 39.4 vs. low IGFBP-3, 18.7 months) was identified. Kaplan-Meier analysis demonstrated that IGFBP-3 expression levels and patients survival time were significantly correlated (P<0.001). Multivariate analysis revealed IGFBP-3 expression to be an independent parameter (P= 0.003). Therefore, low levels of IGFBP-3 expression are associated with advance clinicopathological classification and may be a predictor of poor survival in patients with HCC. Furthermore, these findings suggest that IGFBP-3 may serve as an independent molecular marker for the evaluation of prognosis in patients with HCC.

show abstract

“…We furthermore found a positive association between IGFBP-1 and excretion of IgM indicating that high IGFBP-1 may be associated with glomerular damage. Thus, we were able to confirm decreased levels of IGF-1 and increased levels of IGFBP-1 in type 2 diabetes patients with nephropathy [20]. Furthermore, IGFBP-1 increased to significantly higher levels in patients treated with dalteparin than in placebo-treated ones.…”

Section: Discussionmentioning

confidence: 66%

“…The glomerular mesangial matrix turnover was assessed by measuring the urinary excretion of cytokine transforming growth factor beta 1 (TGF β 1) [18]. Furthermore, we analyzed insulin-like growth factor 1 (IGF-1) and IGF-binding protein 1 (IGFBP-1) since the IGFBP-1 [19] and IGF1 have been shown to be associated with diabetes nephropathy independent of the degree of albumin [20]. It has been speculated that low IGF-1 activity may induce apoptosis or loss of podocytes and thus lead to glomerulosclerosis [21].…”

Section: Introductionmentioning

confidence: 99%

Increased Urine IgM and IgG₂Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes

Torffvit

Kalani

Apelqvist

et al. 2012

Biochemistry Research International

View full text Add to dashboard Cite

Fifty-four type 2 diabetic patients with neuroischemic foot ulcers were randomised to treatment with 5000 IU of dalteparin, (n = 28), or physiological saline, (n = 26), once daily until ulcer healing or for a maximum of 6 months. Thirty-three patients had normo-, 15 micro-, and 6 macroalbuminuria. The urinary levels of IgM and IgG2 were elevated in 47 and 50 patients, respectively. Elevated urinary levels of IgM and IgG2 indicate decreased glomerular size selectivity. Urine IgM levels were associated with IGF-1/IGFBP-1 and IGFBP-1 levels. Dalteparin treatment increased urinary levels of glycosaminoglycans (P < 0.001) and serum IGFBP-1 (P < 0.05) while no significant effects were seen in any of the other studied parameters. In conclusion, dalteparin therapy in patients with type 2 diabetes had no effects on urinary levels of albumin, IgM, or IgG2 despite significantly increased glycosaminoglycans in urine. Elevated urinary levels of IgM and IgG2 might be more sensitive markers of renal disease than albuminuria in patients with type 2 diabetes and antihypertensive therapy.

show abstract

Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus

Cited by 16 publications

References 33 publications

Elevated expression levels of serum insulin‐like growth factor‐1, tumor necrosis factor‐α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy

Elevated expression levels of serum insulin‐like growth factor‐1, tumor necrosis factor‐α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy

Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma

Increased Urine IgM and IgG₂Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About

Association of serum levels of IGF-I and IGFBP-1 with renal function in patients with type 2 diabetes mellitus

Cited by 16 publications

References 33 publications

Elevated expression levels of serum insulin‐like growth factor‐1, tumor necrosis factor‐α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy

Elevated expression levels of serum insulin‐like growth factor‐1, tumor necrosis factor‐α and vascular endothelial growth factor 165 might exacerbate type 2 diabetic nephropathy

Low expression levels of insulin-like growth factor binding protein-3 are correlated with poor prognosis for patients with hepatocellular carcinoma

Increased Urine IgM and IgG2Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes

Contact Info

Product

Resources

About

Increased Urine IgM and IgG₂Levels, Indicating Decreased Glomerular Size Selectivity, Are Not Affected by Dalteparin Therapy in Patients with Type 2 Diabetes